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Abstract 
Square-planar isocyanate and chloride Ni(II) complexes with tridentate PNO condensation 
product of 2-(diphenylphosphino)benzaldehyde and Girard’s T reagent have been synthesized 
and their crystal structures determined. These Ni(II) complexes with different monodentate 
ligands, chloride, cyanate and thiocyanate, were tested for their antimicrobial activities 
against pathogenic microorganisms. The ligand and Ni(II) complexes were active not only 
against laboratory control strains of bacteria and yeast, but also on clinical isolates of E. coli 
and P. aeruginosa strains resistant to most of the clinically used antibiotics. 
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1. Introduction 
The resistance of pathogenic microorganisms to standard antimicrobial agents results 
in a growing demand for development of new drugs. Due to their structural diversity, metal 
complexes, can be a significant source of new chemotherapeutics. Schiff bases are an 
important class of compounds due to their role as ligands in metal coordination chemistry [1–
3]. The coordination properties depend on conformational flexibility of the ligand, the nature 
of the central metal as well as on the presence of other species capable to compete for 
coordination sites. Significant biological activity of Schiff base ligands attracted our attention 
as this frequently increases after complexation with metal ions [1–14]. Schiff bases of 2-
(diphenylphosphino)benzaldehyde continue to be a primary research area of our group. 
Acylhydrazones of 2-(diphenylphosphino)benzaldehyde and their complexes show  
significant antimicrobial activity; in most cases biological activity was enhanced upon 
complexation. A connection between the biological activity and structure of the compounds 
was established. Antimicrobial activity is influenced by geometry, hydrophobicity and charge 
of complexes, so that the highest antibacterial activity was observed for octahedral, 
electrolytic complexes, while square-planar, neutral complexes showed better antifungal 
activity. Also, it was determined that in square-planar complexes a positive charge of the 
ligand led to decrease in antifungal activity and to increase in antibacterial activity. On the 
other hand in the case of octahedral complexes the opposite situation occurs and uncharged 
ligand led to better antibacterial activity, while positively charged ligand led to higher 
antifungal activity [15–19].  
In this paper synthesis and structural characterization of isocyanate ([NiL(NCO)]BF4) 
and chloride ([NiLCl]BF4) Ni(II) complexes with condensation product of 2-
(diphenylphosphino)benzaldehyde and Girard’s T reagent (HLCl) are described (Scheme 1). 
Antimicrobial potential of the newly synthesized Ni(II) complexes ([NiLCl]BF4 and 
[NiL(NCO)]BF4) as well as three previously synthesized related complexes ([NiL(NCS)]BF4, 
[NiL(NCS)]SCN and [NiHL(NCS)3]) with condensation product of 2-
(diphenylphosphino)benzaldehyde and Girard’s T reagent and three different monodentate 
ligands i.e. chloride, cyanate and thiocyanate has been investigated (Scheme 2). 
<Scheme 1> 
<Scheme 2> 
2. Experimental 
2.1. Material and methods 
2-(Diphenylphosphino)benzaldehyde (97%) and Girard’s T reagent (99%) were 
obtained from Aldrich. HLCl was obtained by condensation of 2-
(diphenylphosphino)benzaldehyde and Girard’s T reagent using a previously reported method 
[19]. IR spectra were recorded on a Perkin–Elmer FT-IR 1725X spectrometer using the ATR 
technique from 4000−400 cm−1. Elemental analyses (C, H, and N) were performed by 
standard micro-methods using the ELEMENTARVario ELIII C.H.N.S.O analyzer. Molar 
conductivities were measured at room temperature (23 °C) on a digital conductivity-meter 
JENWAY-4009. UV/Vis spectra were recorded on a Shimadzu 1800 UV/Vis spectrometer. E. 
coli and P. aeruginosa strains (clinical isolates) were kindly supplied by dr Mirjana 
Kovačević, Poliklinika Beo-Lab (Belgrade, Serbia). 
2.2. Synthesis of [NiLCl]BF4 
HLCl, 0.11 g (0.23 mmol), was dissolved, by heating, in ethanol (20 mL) and solid 
Ni(BF4)2·6H2O, 0.08 g, (0.23 mmol), was added. The reaction mixture was heated at 72 oC for 
2 h. The color of the solution changed from green to red. The reaction solution was left to 
stand at room temperature, while orange-reddish crystals arose from the solution. Yield: 0.07 
g (52 %) IR (vs-very strong, s-strong, m-medium, w-weak): 3060 (w), 2969 (w), 1610 (w), 
1572 (s), 1481 (m), 1435 (m), 1334 (m), 1058 (vs), 999 (m), 926 (w), 752 (m), 694 (m), 540 
(w), 504 (w). Elemental analysis calcd for C24H26BClF4N3NiOP: N 7.19 %, C 49.32 %, H 
4.48 %, found: N 7.21 %, C 49.27 %, H 4.51 %. ΛM (1 mM, DMSO): 28 Ω–1 cm2 mol–1. λmax 
(nm) (DMSO): 292, 328, 342 and 364. 
2.3. Synthesis of [NiL(NCO)]BF4 
A mixture of 0.08 g (0.23 mmol) Ni(BF4)2·6H2O and 0.11 g (0.23 mmol) of HLCl was 
dissolved in methanol (20 mL) and then 0.05 g (0.77 mmol) NaOCN was added. The mixture 
was heated at 72 oC for 2 h. The reaction solution was left to stand at room temperature and 
orange crystals arose from the solution. Yield 0.08 g (59 %). IR: 3057 (w), 2190 (vs), 1612 
(w), 1570 (s), 1483 (m), 1436 (m), 1336 (m), 1085 (s), 1048 (s), 1003 (m), 927 (w), 751 (m), 
693 (m), 541 (w), 488 (w). Elemental analysis calcd for C25H26BF4N4NiO2P: N 9.48 %, C 
50.81 %, H 4.43 %, found: N 9.54 %, C 50.79%, H 4.46 %. ΛM (1 mM, DMSO): 29.3 Ω–1 cm2 
mol–1. λmax (nm) (DMSO): 284 and 332. 
2.4. Synthesis of [NiL(NCS)]BF4, [NiL(NCS)]SCN and [NiHL(NCS)3] 
All isothiocyanate complexes of Ni(II) with condensation product of 2-
(diphenylphosphino)benzaldehyde and Girard’s T reagent were synthesized using the 
previously described method [20]. 
 
2.5. X-ray structure determination 
Crystal data and refinement parameters of [NiLCl]BF4 and [NiL(NCO)]BF4 are listed 
in Table 1. The X-ray intensity data were collected at room temperature with an Agilent 
SuperNova dual source using an Atlas detector and equipped with mirror-monochromated Mo 
Kα radiation (λ = 0.71073 Å). The data were processed using CRYSALIS PRO [21]. The 
structures were solved using SIR-92 [22] ([NiLCl]BF4) and Superflip [23] ([NiL(NCO)]BF4). 
All the structures were refined by a full-matrix least-squares procedure based on F2 using 
SHELXL-97 [24]. All non-hydrogen atoms were refined anisotropically. The C6 bonded 
hydrogen in both complexes were located in a difference map and refined with the distance 
restraints (DFIX) with C-H = 0.98 and with Uiso(H) = 1.2Ueq(C). In our final model a very 
large solvent accessible void (1228 Å3) was found in the structure of [NiLCl]BF4. This void is 
probably an indication of solvent molecules (missed in the structure model) present in the unit 
cell and with no chemical meaning. 
<Table 1> 
CCDC 1051742‒1051743 contains the supplementary crystallographic data for [NiLCl]BF4 
and [NiL(NCO)]BF4, respectively. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
2.6.Antimicrobial activity 
Antimicrobial activity was investigated against seven different laboratory control 
strains of bacteria i.e., Gram-positive: Staphylococcus aureus (ATCC 25923), Staphylococcus 
epidermidis (ATCC 12228), Bacillus subtilis (ATCC 6633); Gram-negative: Escherichia coli 
(ATCC 10536), Klebsiella pneumoniae (ATCC 13883), Pseudomonas aeruginosa (ATCC 
27853), and Salmonella enterica subsp. abony (NCTC 6017) and one strain of yeast Candida 
albicans (ATCC 10231). Antibacterial activities of compounds was tested on clinical isolates 
i.e. five E. coli and nine P. aeruginosa strains. 
Minimum inhibitory concentration (MIC) was determined by broth microdilution 
method according to Clinical and Laboratory Standards Institute guidelines [25]. The tested 
compounds were dissolved in 1% DMSO and then diluted to the highest concentration. 
Twofold serial concentrations of the compounds were prepared in a 96-well microtiter plate 
(ranging from 31.2–500 µg/mL) with addition of 0.05% 2,3,5-triphenyl-2H-tetrazolium 
chloride (Sigma-Aldrich) as a growth indicator. All tests were performed in Müller-Hinton 
broth for the bacterial strains and in Sabouraud dextrose broth for C. albicans. All of the MIC 
determinations were performed in duplicate, and two positive growth controls were included. 
Each test was repeated three times. Identical MIC values were obtained in all experiments for 
a particular substance and strain. 
 
3. Results and discussion 
3.1. Synthesis 
Our previous attempts to synthesize Ni(II) complexes with condensation product of 2-
(diphenylphosphino)benzaldehyde and ethyl carbazate or 4-phenylsemicarbazide with 
chloride in the fourth coordination place in the reaction of the appropriate acylhydrazone and 
NiCl2·6H2O in methanolic or ethanolic solutions were unsuccessful since these complexes 
were unstable in reaction solutions and decomposed to starting compounds. The reaction of 
HLCl with Ni(BF4)2·6H2O results in formation of square-planar ([NiLCl]BF4) (Scheme 3). In 
this reaction the source of chloride was the ligand itself. In the reaction of Ni(BF4)2·6H2O and 
NaOCN with HLCl in methanol [NiL(NCO)]BF4 was obtained (Scheme 3). In ([NiLCl]BF4 
and [NiL(NCO)]BF4) coordination spheres contain deprotonated zwitter-ionic form of 
acylhydrazone ligand coordinated in tridentate PNO fashion and monodentate chloride or 
cyanate in the fourth coordination position. 
<Scheme 3> 
The reactions of acylhydrazones of 2-(diphenylphosphino)benzaldehyde with Ni2+ and 
OCN– resulted in four-coordinate metal ion formation [17, 18, 26]. Geometries of these 
cyanate Ni(II) complexes depend on the nature of the acylhydrazone i.e. tetrahedral complex 
was obtained with condensation product of 2-(diphenylphosphino)benzaldehyde and 
semioxamazide [26], while square-planar complexes were formed with condensation product 
of 2-(diphenylphosphino)benzaldehyde and ethyl carbazate [17] or 4-phenylsemicarbazide 
(Scheme 4) [18]. Ambidentate OCN– could be coordinated via N or O and both types of 
coordination were observed. Theoretical calculations at OPBE/TZ2P level have shown that 
Ni–N coordination is favored by 17.0 kcal mol–1 for NCO– vs. OCN– [18]. 
<Scheme 4> 
Syntheses of [NiL(NCS)]BF4, [NiL(NCS)]SCN and [NiHL(NCS)3] were previously 
described [20]. Reaction conditions i.e. the source of Ni2+ and SCN– influenced stoichiometry 
and geometry of complexes. Coordination of ligand in deprotonated zwitter-ionic form results 
in formation of square-planar complexes, while coordination of monocationic form of 
undeprotonated ligand leads to octahedral geometry [20]. 
3.2.Crystal structures of [NiLCl]BF4 and [NiL(NCO)]BF4 
[NiLCl]BF4 and [NiL(NCO)]BF4 crystallized in monoclinic and orthorhombic crystal 
systems with space groups C2/c and Pbca, respectively. ORTEP of the structures are given in 
Figs. 1 and 2, while bond lengths and angles are listed in Table 2. The complex cations in 
[NiLCl]BF4 and [NiL(NCO)]BF4 consist of one tridentate deprotonated PNO ligand 
coordinated to Ni(II) and coordinated chloride or isocyanate forming a square planar 
geometry. BF4‒ ion acts as counterion in the crystal structure of both complexes. Bond 
distances and angles in [NiLCl]BF4 and [NiL(NCO)]BF4 are in accord with reported values 
for the similar square-planar complex where thiocyanate is coordinated through nitrogen to Ni 
[20]. The sum of the nickel-containing angles in [NiLCl]BF4 and [NiL(NCO)]BF4 is 360°. 
The position of Ni(II) is 0.0520(13) ([NiLCl]BF4) and 0.0039(10) ([NiL(NCO)]BF4) out of 
the best plane that contained the coordination sphere. In the structures of both complexes 
there is no evidence for significant non-covalent interactions. 
<Figure 1> 
<Figure 2> 
<Table 2> 
 3.3. Spectroscopy  
 
In IR spectra of complexes instead of the carbonyl band of the uncoordinated ligand at 
1686 cm–1 a new band appeared at 1572 cm–1 in the spectrum of [NiLCl]BF4 and at 1570 cm–1 
in the spectrum of [NiL(NCO)]BF4. The observed bands indicate coordination of the ligand in 
deprotonated form via carbonyl oxygen and electron delocalization [N=C–O– ↔ –N–C=O] of 
the deprotonated hydrazide in the bound ligand. Coordination of imine nitrogen was 
confirmed from the batochromic shifts of ν(C=N) from 1657 cm–1 in the spectrum of the free 
ligand to 1610 and 1612 cm–1 in spectra of [NiLCl]BF4 and [NiL(NCO)]BF4, respectively. 
Similarly as in the case with previously reported Ni(II) complexes of 2-
(diphenylphosphino)benzaldehyde acylhydrazone ligands there are no significant changes in 
position of ν(C–P) vibration (1433 cm–1 in the spectrum of ligand, 1435 cm–1 in the spectrum 
of [NiLCl]BF4 and 1436 cm–1 in the spectrum of [NiL(NCO)]BF4) [17, 18, 20, 26]. A band at 
2190 cm–1 observed in the IR spectrum of [NiL(NCO)]BF4 corresponds to cyanate 
coordination. The appearance of strong bands at 1058 cm–1 in the spectrum of [NiLCl]BF4 
and at 1048 cm–1 in the spectrum of [NiL(NCO)]BF4 indicates the presence of 
tetrafluoroborate in the outer sphere of both complexes.  
 
3.4. Antimicrobial activity 
All the complexes showed moderate activity against all the tested microorganisms. 
The ligand and the complexes showed similar activities. [NiL(NCS)]BF4 showed the best 
activity against B. subtilis and P. aeruginosa, [NiL(NCS)]SCN against S. epidermidis and B. 
subtilis, [NiL(NCO)]BF4 against S. aureus, B. subtilis and P. aeruginosa, [NiLCl]BF4 against 
S. aureus and B. subtilis, while in the case of [NiHL(NCS)3] the same activity was observed 
against all the tested microbial strains. All the tested compounds, except [NiHL(NCS)3], 
exhibited best activity against B. subtilis although with this strain the highest activity was 
observed for ligand itself (Table 3). The activities of all complexes to K. pneumoniae, all 
complexes except [NiHL(NCS)3] to B. subtilis, the newly synthesized complexes to S. aureus 
and isocyanate and isothiocyanate complexes with BF4- as the counterion to P. aeruginosa are 
similar to cefotaxime. Of particular significance is the fact that the ligand and Ni(II) 
complexes showed moderate activity against P. aeruginosa (Table 4) and E. coli (Table 5) 
strains (clinical isolates from different origin) resistant to most of the clinically used 
antibiotics. 
<Table 3> 
<Table 4> 
<Table 5> 
 
4. Conclusion 
The synthesized square-planar Ni(II) complexes contain a common tridentate ligand, 
condensation product of 2-(diphenylphosphino)benzaldehyde and Girard’s T reagent, 
coordinated in deprotonated zwitter-ionic form via phosphorus, imine nitrogen and carbonyl 
oxygen and chloride or isocyanate in the fourth coordination site. Tetrafluoroborate is in the 
outer sphere of both complexes. Condensation product of 2-
(diphenylphosphino)benzaldehyde and Girard’s T reagent and corresponding isocyanate, 
chloride and isothiocyanate complexes possess antimicrobial properties. Comparison of their 
antimicrobial activity with the activity of previously examined Ni(II) complexes with 
acylhydrazones of 2-(diphenylphosphino)benzaldehyde [17,18] suggests that the presence of 
quaternary ammonium group in the structure of ligand significantly improves antibacterial 
activity.  
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 Table 1. Crystal data and structure refinement details for [NiLCl]BF4 and [NiL(NCO)]BF4. 
 [NiLCl]BF4 [NiL(NCO)]BF4 
formula  C24H26BClF4N3NiOP C25H26BF4N4NiO2P 
Fw (g mol
–1
) 584.42 590.99 
crystal size (mm) 0.50  0.30  0.20 0.40  0.30  0.10 
crystal color red Red 
crystal system monoclinic Orthorhombic 
space group C2/c Pbca 
a (Å) 26.6563(18) 12.5489(2) 
b (Å) 10.4868(3) 15.1189(2) 
c (Å) 25.6357(17) 27.5476(4) 
β (º) 123.101(9) 90.00 
V (Å
3
) 6003.2(6) 5226.48(13) 
Z 8 8 
calcd density (g cm
-3
) 1.293 1.502 
F(000) 2400 2432 
no. of collected reflns 15346 46640 
no. of independent reflns 6878 5987 
Rint 0.0232 0.0319 
no. of reflns observed 5470 4747 
no. parameters 331 349 
R[I > 2σ (I)]a 0.0598 0.0379 
wR2 (all data)
b
 0.2088 0.1050 
Goof , S
c
 1.052 1.031 
maximum/minimum residual 
electron density (e Å
–3
)  
+1.02/–0.60 +0.54/–0.35 
a
 R = ∑||Fo| – |Fc||/∑|Fo|. 
b
 wR2 = {∑[w(Fo
2
 – Fc
2
)
2]/∑[w(Fo
2
)
2
]}
1/2
. 
 c S = {∑[(Fo
2 – Fc
2)2]/(n/p}1/2 where n is the number of reflections and p is the total number of parameters 
refined. 
 Table 2. Selected bond lengths (Å) and angles (°) for [NiLCl]BF4 and [NiL(NCO)]BF4. 
 [NiLCl]BF4  [NiL(NCO)]BF4 
Ni1–Cl1  2.1550(10)   
Ni1–N2 1.863(3)  1.8542(18) 
Ni1–N4   1.851(2) 
Ni1–O1 1.891(2)  1.8896(15) 
Ni1–P1 2.1358(9)  2.1477(6) 
N1–N2 1.422(4)  1.413(3) 
N1–C5 1.293(5)  1.299(3) 
N2–C6 1.294(5)  1.288(3) 
O1–C5 1.281(5)  1.274(3) 
    
P1–Ni1–Cl1 90.32(4)   
P1–Ni1–N2 94.70(9)  95.97(6) 
P1–Ni1–N4   89.05(7) 
P1–Ni1–O1 173.13(9)  178.26(6) 
N2–Ni1–Cl1 174.95(10)   
N2–Ni1–N4   174.81(9) 
N2–Ni1–O1 83.85(12)  84.14(7) 
N1–N2–C6 112.5(3)  112.51(18) 
N1–C5–O1 124.7(3)  125.4(2) 
N2–N1–C5 109.3(3)  108.75(18) 
N4–C25–O2   176.0(3) 
 Table 3. Antimicrobial activity of tested compounds (MIC values are given in mM)  
Microorga
nism 
HL
Cl 
[NiHL(N
CS)3] 
[NiL(NCS
)]BF4 
[NiL(NCS)
]SCN 
[NiL(NCO
)]BF4 
[NiLCl]
BF4 
Ni(BF4)2·
6H2O 
NaO
CN 
KSC
N 
Cefotax
ime 
Amphote
ricin B 
S. aureus 
ATCC 
25923 
0.1
29 
0.191 0.206 0.210 0.106 0.107 1.469 
7.69
1 
5.14
5 0.027 n.t. 
S. 
epidermid
is 
ATCC 
1228 
0.2
57 
0.191 0.206 0.105 0.212 0.214 1.469 
>7.6
91 
>5.1
45 
0.007 n.t. 
B. subtilis 
ATCC 
6633 
0.0
64 
0.191 0.103 0.105 0.106 0.107 1.469 
>7.6
91 
>5.1
45 0.027 n.t. 
K. 
pneumoni
ae 
ATCC 
13883 
0.2
57 
0.191 0.206 0.210 0.212 0.214 1.469 
>7.6
91 
>5.1
45 
0.055 n.t. 
E. coli 
ATCC 
25922 
0.2
57 
0.191 0.206 0.210 0.212 0.214 >1.469 
>7.6
91 
>5.1
45 0.014 n.t. 
S. enterica 
NCTC 
6017 
0.2
57 
0.191 0.206 0.210 0.212 0.214 1.469 
>7.6
91 
>5.1
45 0.007 n.t. 
P. 
aeruginos
a 
ATCC 
27853 
0.2
57 
0.191 0.103 0.210 0.106 0.214 >1.469 
>7.6
91 
>5.1
45 
0.027 n.t. 
C. 
albicans 
ATCC 
10231 
0.2
57 
0.191 0.206 0.210 0.212 0.214 1.469 
7.69
1 
>5.1
45 
n.t. 0.007 
 Table 4. Antibacterial activity of tested compounds against different P. aeruginosa isolates (MIC values 
are given in mM) 
 
1a 
(uroculture) 
2b 
(wound) 
3c 
(uroculture) 
4d 
(wound) 
5d 
(wound) 
6e 
(ear) 
7e 
(ear) 
8f 
(uroculture) 
9g 
(uroculture) 
HLCl 0.257 0.257 0.514 0.257 0.257 0.257 0.257 0.257 0.257 
[NiHL(NCS)3] 0.191 0.191 0.191 0.191 0.191 0.191 0.191 0.191 0.191 
[NiL(NCS)]SCN 0.210 0.210 0.210 0.210 0.210 0.210 0.210 0.210 0.210 
[NiL(NCO)]BF4 0.212 0.212 0.212 0.212 0.212 0.212 0.212 0.212 0.212 
[NiLCl]BF4 0.214 0.214 0.214 0.214 0.214 0.214 0.214 0.214 0.214 
 
resistant to: a amoxiclav, cefixime, cephalexin, fosfomycin, nitrofurantoin, sulfamethoxazole/trimethoprim; b 
amoxiclav, ampicillin, cefixime, cephalexin, sulfamethoxazole/trimethoprim; c amoxiclav, ampicillin, cefixime, 
ciprofloxacin, cephalexin, ceftriaxone, cefepime, gentamicin, sulfamethoxazole/trimethoprim;d amoxiclav, 
cefixime, cephalexin, sulfamethoxazole/trimethoprim; e amoxiclav, ampicillin, cefixime, cephalexin, 
chloramphenicol, tetracycline, sulfamethoxazole/trimethoprim ;f amoxiclav, cefixime, ciprofloxacin, cephalexin, 
gentamicin, fosfomycin, pipemidic acid, sulfamethoxazole/trimethoprim;g amoxiclav, ampicillin, cefixime, 
ciprofloxacin, cephalexin, ceftriaxone, cefepime, gentamicin, sulfamethoxazole/trimethoprim 
 Table 5. Antibacterial activity of tested compounds against E. coli strains isolated from uroculture (MIC 
values are given in mM) 
 HLCl [NiHL(NCS)3] [NiL(NCS)]BF4 [NiL(NCS)]SCN [NiL(NCO)]BF4 [NiLCl]BF4 
1a
 
0.514 0.381 0.206 0.210 0.423 0.214 
2b
 
0.514 0.381 0.206 0.210 0.423 0.214 
3c
 
0.514 0.381 0.206 0.210 0.423 0.214 
4d
 
0.514 0.381 0.412 0.210 0.423 0.214 
5e
 
0.514 0.381 0.206 0.210 0.423 0.214 
 
resistant to: a amoxiclav, piperacillin, cephalexin, cefepime, cefixime, ceftazidime, ceftriaxone, ciprofloxacin, 
gentamicin, pipemidic acid; b ciprofloxacin, gentamicin, sulfamethoxazole/trimethoprim, pipemidic acid; c 
amoxiclav, cephalexin; d nalidixic acid; e ampicillin, sulfamethoxazole/trimethoprim 
Scheme caption  
Scheme 1. Synthesis of HLCl. 
Scheme 2. Square-planar (a) and octahedral (b) Ni(II) complexes with condensation product 
of 2-(diphenylphosphino)benzaldehyde and Girard’s T reagent and different monodentate 
ligands. 
Scheme 3. Synthesis of [NiLCl]BF4 and [NiL(NCO)]BF4. 
Scheme 4. a) Synthesis of cyanate Ni(II) complex with condensation product of 2-
(diphenylphosphino)benzaldehyde and semioxamazide; b) Synthesis of cyanate Ni(II) 
complex with condensation product of 2-(diphenylphosphino)benzaldehyde and ethyl 
carbazate; c) Synthesis of isocyanate Ni(II) complex with condensation product of 2-
(diphenylphosphino)benzaldehyde and 4-phenylsemicarbazide. 
Figure caption 
Figure 1. ORTEP plot of [NiLCl]BF4 with thermal ellipsoids at 50% probability for non-H 
atoms and circles for hydrogens. The BF4– was omitted for clarity. 
Figure 2. ORTEP plot of [NiL(NCO)]BF4 with thermal ellipsoids at 50% probability for non-
H atoms and circles for hydrogens. The BF4– was omitted for clarity. 
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